Today: 7 February 2026
Subscribe
Browse Category

NASDAQ:PRAX News 16 October 2025 - 14 January 2026

Praxis Precision Medicines (PRAX) stock jumps after Devinsky hire as FDA filings loom

Praxis Precision Medicines (PRAX) stock jumps after Devinsky hire as FDA filings loom

Shares of Praxis Precision Medicines rose about 8% to $303.23 by mid-afternoon Wednesday after the company named epilepsy specialist Dr. Orrin Devinsky as head of clinical strategy. Investors are watching two FDA drug applications set for mid-February. Praxis recently raised $575 million in a public offering. The broader biotech sector outperformed the market, while major indexes fell.
14 January 2026
·
Praxis Precision stock rises as $575 million share sale clears at $260

Praxis Precision stock rises as $575 million share sale clears at $260

NEW YORK, Jan 7, 2026, 12:02 PM EST — Regular session Praxis Precision Medicines shares rose about 6% on Wednesday after the biotech priced a $575 million public offering overnight, even as the deal came at a discount to the prior close. GlobeNewswire The Boston-based company late Tuesday set the offering at $260 per share for 2.212 million shares, and gave underwriters a 30-day option to buy up to 331,800 more shares. The deal is expected to close on or about Jan. 8, the company said. GlobeNewswire The stock was last at about $289.5 in midday trading, versus Tuesday’s close
7 January 2026
·
Why Praxis Precision Medicines (PRAX) stock is down today after FDA breakthrough nod for its tremor drug

Why Praxis Precision Medicines (PRAX) stock is down today after FDA breakthrough nod for its tremor drug

NEW YORK, December 30, 2025, 14:54 ET — Regular session Shares of Praxis Precision Medicines Inc (NASDAQ: PRAX) slipped about 3% on Tuesday, giving back part of a sharp rally sparked by an FDA regulatory boost for its lead essential tremor program. The stock was down 3% at $295.50 as of 2:39 p.m. ET, after opening at $304.00 and trading between $286.58 and $304.70. The company said on Monday the U.S. Food and Drug Administration granted Breakthrough Therapy Designation for ulixacaltamide to treat essential tremor, and said the decision was based on positive topline results from the Essential3 program, two
30 December 2025
··
Praxis Precision Medicines stock jumps after FDA Breakthrough Therapy tag for tremor drug, BTIG lifts target

Praxis Precision Medicines stock jumps after FDA Breakthrough Therapy tag for tremor drug, BTIG lifts target

NEW YORK, December 30, 2025, 05:21 ET — Premarket Praxis Precision Medicines Inc shares rose 13.25% on Monday to close at $304.58, after the U.S. Food and Drug Administration granted Breakthrough Therapy Designation for its essential tremor candidate ulixacaltamide, a filing showed. The stock opened at $317.72 and traded between $298 and $317.72, and was down about 1% in after-hours trading. StockAnalysis+2SEC+2 Breakthrough Therapy Designation is an FDA pathway meant to speed development and review for drugs aimed at serious conditions when early clinical evidence suggests a meaningful step up over available therapies. For traders, it often serves as a
30 December 2025
···
Praxis Precision Medicines (PRAX) stock jumps 13% after FDA breakthrough designation for tremor drug

Praxis Precision Medicines (PRAX) stock jumps 13% after FDA breakthrough designation for tremor drug

NEW YORK, December 30, 2025, 00:52 ET — Market closed. Praxis Precision Medicines shares climbed about 13% in Monday’s session, last trading at $304.58, after the company said U.S. regulators granted Breakthrough Therapy Designation for its experimental essential tremor treatment. The stock swung between $318.08 and $275.00 during the day. The designation, known as BTD, is an FDA pathway meant to speed development and review of drugs for serious conditions when early clinical evidence suggests a meaningful improvement over available options. U.S. Food and Drug Administration Praxis said the BTD was granted for ulixacaltamide and that it expects to submit
30 December 2025
··
Praxis Precision Medicines (PRAX) Soars on FDA Momentum and 760-Dollar Target: December 9, 2025 Stock Deep Dive

Praxis Precision Medicines (PRAX) Soars on FDA Momentum and 760-Dollar Target: December 9, 2025 Stock Deep Dive

Praxis Precision Medicines, Inc. (NASDAQ: PRAX) has turned into one of 2025’s most dramatic biotech stories. On December 9, 2025, the stock is trading around $265–270 per share, near its 52‑week high of about $278 and far above its low near $26.70, giving the company a market capitalization of roughly $6.6 billion.StockAnalysis+1 Behind that move is a mix of powerful late‑stage clinical data, accelerating FDA interactions, increasingly aggressive analyst targets — including a new $760 price target from Guggenheim — and a growing cloud of controversy after a short‑seller attack on Praxis’s lead program.Quiver Quantitative+2Investing.com+2 Here is a detailed, news-style
9 December 2025
·
Praxis Precision Medicines (PRAX) Stock Soars After Epilepsy Breakthrough and FDA Pre‑NDA Win

Praxis Precision Medicines (PRAX) Stock Soars After Epilepsy Breakthrough and FDA Pre‑NDA Win

Praxis Precision Medicines, Inc. (NASDAQ: PRAX) ripped higher again on 5 December 2025, extending one of the most dramatic biotech rallies of the year after positive epilepsy data and a favorable pre‑NDA meeting with the FDA. By the closing bell on Friday, PRAX finished at $247.99, up 30.5% on the day, with a new 52‑week range of $26.70–$277.44 and a market capitalization around $6.2 billion. StockAnalysis+1 Below is a deep dive into the latest news, forecasts, and analysis as of 5 December 2025, and what they may mean for investors watching PRAX stock. Key Takeaways PRAX Stock Today: A Volatile
6 December 2025
·
Biggest Stock Gainers Today (December 5, 2025): TGL, SMX, WHLR, DBRG, TORO, PRAX and RBRK Lead a Volatile Session

Biggest Stock Gainers Today (December 5, 2025): TGL, SMX, WHLR, DBRG, TORO, PRAX and RBRK Lead a Volatile Session

The U.S. stock market logged another upbeat session on Friday, December 5, 2025, with the S&P 500, Nasdaq 100 and Dow all edging higher. But beneath the index-level moves, a cluster of highly volatile small caps, high‑growth tech names and a few mid‑caps stole the show with spectacular double‑ and even triple‑digit gains. StockAnalysis+1 Below is a breakdown of the biggest stock gainers today, why they moved, and what recent forecasts and analyst commentary suggest about their outlooks. All data and price moves refer to the U.S. session on December 5, 2025, unless otherwise noted. Top 10 Biggest U.S. Stock Gainers Today (By
6 December 2025
············
Praxis Precision Medicines (PRAX) Stock Surges on FDA Progress and Epilepsy Trial Wins: Latest News and 2026 Forecast

Praxis Precision Medicines (PRAX) Stock Surges on FDA Progress and Epilepsy Trial Wins: Latest News and 2026 Forecast

Updated December 5, 2025 – all developments since December 4, 2025 Praxis Precision Medicines, Inc. (NASDAQ: PRAX) has moved back into the market spotlight after a flurry of major announcements on December 4, 2025. The biotech’s stock — already one of 2025’s wildest movers — is reacting to fresh positive data in rare epilepsies and new regulatory momentum for its lead essential tremor drug. Below is a structured rundown of what has happened since December 4, 2025, how analysts now value PRAX stock, and what investors are watching into 2026. This article is for information only and is not financial
5 December 2025
·
Praxis Precision (PRAX) Stock Skyrockets on Game-Changing Phase 3 Results – What Experts Say

Praxis Precision (PRAX) Stock Skyrockets on Game-Changing Phase 3 Results – What Experts Say

Market Outlook With the stock now trading well above $150, investors are debating how much further PRAX could rise. If ulixacaltamide wins approval, analysts believe it could capture a sizable ET market. However, success in neurology trials can be binary – failures or setbacks could send the stock sharply down. Looking ahead, Praxis expects more data by late 2025/early 2026 (e.g. vormatrigine POWER1 topline, PRAX-562 EMBOLD readoutnasdaq.comneurologylive.com). Management’s guidance (via press releases and presentations) has focused on these milestones rather than concrete revenue forecasts, which is typical for clinical-stage biotechsnasdaq.com. In the near term, analysts will scrutinize FDA feedback and
16 October 2025
··

Stock Market Today

GE Vernova stock price jumps toward $800 — what to know before Monday trade

GE Vernova stock price jumps toward $800 — what to know before Monday trade

7 February 2026
GE Vernova shares jumped 5.7% to $779.35 Friday after Baird upgraded the stock and the Dow closed above 50,000. The company’s onshore wind unit reported 1.1 GW in U.S. repower orders for 2025, a figure previously disclosed. GE Vernova also completed a $2.6 billion senior notes offering to help fund its Prolec GE stake purchase. Next earnings report is set for April 22.
Go toTop